Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kiniksa Pharmaceuticals (KNSA)
NASDAQ:KNSA
RESEARCH TOOLSreports
Holding KNSA?
Track your performance easily
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
―Last Year’s EPS
―Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 29, 2024
|% Change Since: -27.73%
|Next Earnings Date:Feb 26, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and increased sales guidance, driven by high prescriber satisfaction and effective educational initiatives. However, challenges remain with net losses and patient misdiagnosis rates. Overall, the positive aspects of revenue growth and strategic initiatives outweigh the negatives.Company Guidance
During the Kiniksa Pharmaceuticals Q3 2024 earnings call, the company increased its full-year net sales guidance for ARCALYST to between $410 million and $420 million, up from the previous range of $405 million to $415 million. The third quarter saw ARCALYST net product revenue grow by 73% year-over-year, reaching $112.2 million. Key metrics included a rise in total prescribers from approximately 2,300 to approximately 2,550, with about 25% of them writing multiple prescriptions. The average duration of therapy increased to 27 months, and patient compliance remained above 85%. The company also noted a high payer approval rate above 90% for completed cases. Additionally, they reported a net loss of $12.7 million for the quarter, a slight improvement from a $13.9 million loss in the same period last year, and ended the quarter with a cash balance of $223.8 million.Increased Full-Year Sales Guidance
Kiniksa increased its full-year ARCALYST net sales guidance to between $410 million to $420 million, up from the previous range of $405 million to $415 million.
Strong ARCALYST Revenue Growth
ARCALYST net product revenue grew 73% year-over-year, delivering $112.2 million of net product revenue for the quarter.
High Prescriber and Patient Satisfaction
Patient compliance remains above 85%, with greater than 90% payer approval of completed cases, and an increase in repeat prescriber rates.
Educational Initiatives
Launched Life DisRPted campaign with celebrities to increase disease awareness, and sponsored the American Heart Association's initiative to improve care for recurrent pericarditis patients.
---
KNSA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
KNSA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 29, 2024 | $27.59 | $23.26 | -15.69% |
| Jul 23, 2024 | $26.29 | $25.20 | -4.15% |
| Apr 23, 2024 | $17.10 | $17.68 | +3.39% |
| Feb 28, 2024 | $20.89 | $20.36 | -2.54% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Kiniksa Pharmaceuticals (KNSA) report earnings?
Kiniksa Pharmaceuticals (KNSA) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is Kiniksa Pharmaceuticals (KNSA) earnings time?
Kiniksa Pharmaceuticals (KNSA) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KNSA EPS forecast?
Currently, no data Available
---